

IntelGenx Technologies Corp.  
Form 8-K  
May 29, 2012

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**Current Report  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**May 28, 2012**  
Date of Report (Date of Earliest Event Reported)

**IntelGenx Technologies Corp.**

**(Exact Name of Registrant as Specified in its Charter)**

<b><u>Delaware</u></b> (State or other jurisdiction of incorporation)	<b><u>000-31187</u></b> (Commission File Number)	<b><u>870299034</u></b> (IRS Employer Identification No.)
<b><u>6425 Abrams, Ville St- Laurent, Quebec, Canada</u></b> (Address of principal executive offices)		<b><u>H4S 1X9</u></b> (Zip Code)

Registrant's telephone number, including area code: (514) 331-7440

Check the appropriate box below if the Form 8K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17CFR230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a -12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
- Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
-

**Item 7.01 Regulation FD Disclosure - News Release**

**IntelGenx Achieves Positive Pivotal Study Results for Bioequivalent Anti-Migraine VersaFilm Formulation of Maxalt-MLT®**

Exhibit	Description
<u>99.1</u>	<u>Press Release</u>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**INTELGENX TECHNOLOGIES CORP.**

Dated: May 29, 2012

By: */s/ Horst Zerbe*

-----  
Horst G.Zerbe  
President and Chief  
Executive Officer